10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals-Reference-Cited by-同舟云学术

10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

Published:2020-01-01 Issue:1 Volume:12 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Tourdot S.¹,Abdolzade-Bavil A.²,Bessa J.³,Broët P.⁴,Fogdell-Hahn A.⁵,Giorgi M.⁶,Jawa V.⁷,Kuranda K.⁸,Legrand N.⁹,Pattijn S.¹⁰,Pedras-Vasconcelos J. A.¹¹,Rudy A.¹²,Salmikangas P.¹³,Scott D. W.¹⁴,Snoeck V.¹⁵,Smith N.¹⁶,Spindeldreher S.¹⁷,Kramer D.¹⁸

Affiliation:

1. BioMedicine Design, Pfizer Inc, Andover, MA, USA

2. Large Molecule Bioanalytical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Hoffmann-La Roche Ltd, Germany

3. Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Hoffmann-La Roche Ltd, Basel, Switzerland

4. Faculty of Medicine Paris-Saclay, Orsay, France

5. Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

6. Certara QSP, Certara UK Limited, UK

7. Predictive and Clinical Immunogenicity, PPDM, Merck & Co, Kenilworth, NJ, USA

8. Translational Department, Sparks Therapeutics, Philadelphia, PA, USA

9. GenOway, Lyon, France

10. ImmunXperts SA, Gosselies, Belgium

11. Office of Biotechnology Products, CDER, Food and Drug Administration, USA

12. HEXAL AG, Holzkirchen, Germany

13. NDA Advisory Services Ltd, Surrey, UK

14. Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

15. Translational Biomarkers and Bioanalysis, UCB Biopharma SRL, Braine-l’Alleud, Belgium

16. Lonza, Slough, UK

17. Integrated Biologix GmbH, Basel, Switzerland

18. Sanofi R&D, Translational Medicine & Early Development, Sanofi, Frankfurt am Main, Germany

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1725369

Reference20 articles.

1. Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

2. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

3. Inhibitors in haemophilia: pathophysiology

4. Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of Immunogenicity Assessment of Biosimilar Monoclonal Antibodies in the United States;Clinical Pharmacology & Therapeutics;2023-09-11

2. International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs;Clinical and Translational Science;2023-02-02

3. Untoward immune effects of modern medication;The Journal of Biomedical Research;2023

4. Condon Optimization: Codon Optimization of Therapeutic Proteins: Suggested Criteria for Increased Efficacy and Safety;Single Nucleotide Polymorphisms;2022

5. Investigation of Factors Associated With Immunogenicity Labeling Updates and Characteristics of Biologics License Applications;Clinical Pharmacology & Therapeutics;2021-08-24